11
Aug

Denmark’s Forward Pharma has a plan to contend with Biogen Idec and its multibillion-selling multiple sclerosis drug Tecfidera, eyeing $200 million in a U.S. IPO to bankroll its offensive.

…read more

Source: Forward Pharma sets sights on Biogen with a $200M IPO

    

0 No comments